PIPELINE
Advancing Parvus pMHC nanomedicine technology for autoimmune diseases
and chronic inflammatory conditions
Parvus’ pipeline programs address a broad range of autoimmune diseases with compelling unmet needs.
The Parvus lead pMHC nanomedicine drug candidate (PVT201) has shown disease modification and hepatoprotection in preclinical models of primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis. The Parvus pipeline includes additional pMHC nanomedicine drug candidates for inflammatory bowel disease, type-1 diabetes, multiple sclerosis, rheumatoid arthritis, transplant rejection prevention, and celiac disease.